On October 26, 2026, Bio-Thera Solutions announced that China’s National Medical Products Administration (“NMPA”) approved BAT2306, its biosimilar to COSENTYX® (secukinumab). BAT2306 will be marketed as YOUZHUOMEI® and is approved for psoriasis, ankylosing spondylitis, and psoriatic arthritis. According to Bio-Thera, BAT2306 is the first secukinumab biosimilar approved in China. Bio-Thera…
